Press |

Foundation Dutch Uro-Oncology Studygroup (DUOS)

Foundation Dutch Uro-Oncology Study group (DUOS) is a multidisciplinary study group comprising 26 academic and regional hospitals in the Netherlands. Our key interest is initiating and collaborating in investigator as well as Industry initiated and sponsored clinical trials in Urological cancers. The spectrum includes the entire range of metastatic and non- metastatic and phase 1-3 clinical trials as well as post-marketing (phase 4) health- economics studies. DUOS collaborates with other national groups, such as the Scandic Group, the Spanish Oncology Genitourinary Group (SOGUG), as well as Oncology Trials Insights (OTI) in the United States.

In addition DUOS provides information on latest developments and ongoing research for health care professionals and patients. Study group members support patients seeking KOL second opinions. This may include enrollment of potential patients onto DUOS clinical research programs at one of the participating sites.

The group has received financial launching support from the Dutch Cancer Society. The  board currently comprises two urologists: dr. Inge van Oort (Radboud UMC, Nijmegen) and dr. Joost Boormans (ErasmusMC Cancer Institute, Rotterdam); two radiotherapists: dr. Fons van den Bergh (UMCG, Groningen) and prof. Luca Incrocci (ErasmusMC Cancer Institute, Rotterdam); and two medical oncologists, dr. Andre Bergman (Netherlands Cancer Institute, Amsterdam) and Professor Ronald de Wit (ErasmusMC Cancer Institute, Rotterdam, founding Chairman of DUOS). DUOS is registered by the Netherlands Chamber of Commerce.

The NePro study (docetaxel +/- risedronic acid in mCRPC);  Mainsail (docetaxel +/- lenalidomide), Affirm (MDV3100) and Millenium’s (TAK700/Orteronel) phase 3 studies pre and post docetaxel are examples of DUOS trials. Ongoing are always at least twenty studies, for example:

1. Anti PD-1, a Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer;

2. Cabaresc, a randomized phase 2 trial investigating the role of  budesonide to cabazitaxel chemotherapy;

3. Probach;

4. Capri, Pro Capri;

5. CirGuidance. identification of muscle-invasive bladder cancer patients who will not benefit from neoadjuvant chemotherapy using circulating tumor cells

Studies and sites:,  STUDIES.

More information:

DUOS c/0 Prof Ronald de Wit
Dept. Of Medical Oncology
P.O. Box 5201
3008 AE Rotterdam
tel. + 31 10-704 15 05

DUOS secretariat: /



© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in